Skip to main content
. 2010 Sep 24;10:510. doi: 10.1186/1471-2407-10-510

Table 2.

Tumor characteristics

All patients (n = 282) Patients without visceral metastasis (n = 220) Patients with visceral metastasis (n = 62)

Curative treatment (n = 151) BSC
(n = 69)
Palliative treatment (n = 30) BSC
(n = 32)
Tumoral stage
stage I 27 (9.7%) 24 (15.9%) 3 (4.3%) - -
stage II 68 (24.5%) 61 (40.4%) 7 (10.1%) - -
stage III 69 (24.9%) 51 (33.8%) 18 (26.1%) - -
stage IV (M1a) 8 (2.9%) 7 (4.6%) 1 (1.4%) - -
stage IV (M1b) 62 (22.4%) - - 30 (100%) 32 (100%)
unknown but M0 48 (17.0%) 8 (5.3%) 40 (58.0%) - -
Tumoral location
lower third 151 (53.5%) 80 (60.0%) 37 (53.6%) 19 (63.3%) 15 (46.9%)
middle third 86 (30.6%) 44 (29.1%) 21 (30.4%) 9 (30.0%) 12 (37.5%)
upper third 45 (16.0%) 27 (17.9%) 11 (15.9%) 2 (6.7%) 5 (15.6%)
Mean tumor length
(n = 199, cm, SD)
5.2 ± 2.5 4.7 ± 2.3 5.4 ± 2.6 5.9 ± 1.8 7.2 ± 3.2
Tumor length ≥ 5 cm 116/199 (58.3%) 66/124 (53.2%) 25/43 (58.1%) 11/14 (78.6%) 14/18 (77.8%)
Mean tumor diameter
(n = 81, cm, SD)
2.7 ± 1.3 2.6 ± 1.2 4.1 ± 1.2 * 2.5 ± 0.7 1.9 ± 0.1

Histological type(n = 271)
SCC 183 (67.5%) 103 (70.1%) 45 (70.3%) 17 (56.7%) 18 (60.0%)
adenocarcinoma 83 (30.6%) 44 (29.9%) 18 (28.1%) 12 (40.0%) 9 (30.0%)
other 5 (1.8%) 0 1 (1.5%) 1 (3.3%) 3 (10.0%)

n: number of patients, cm: centimeter, SD: standard deviation, BSC: best supportive care,

SCC: squamous cell carcinoma, *: p < 0.05 curative treatment vs BSC,

: not available for all patients